Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course

Bipolar Disorders

Volumn 18, Issue 4, 2016, Pages 373-378

  Mansur, Rodrigo B ^a,b   Santos, Camila M ^a   Rizzo, Lucas B ^a,c   Asevedo, Elson ^a   Cunha, Graccielle R ^a   Noto, Mariane N ^a,d   Pedrini, Mariana ^a   Zeni Graiff, Maiara ^a   Cordeiro, Quirino ^e   Vinberg, Maj ^f   Kapczinski, Flavio ^g   McIntyre, Roger S ^b   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Vila Maria Outpatient Clinic   (Brazil)

^e IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

bipolar disorder; brain derived neurotrophic factor; diabetes; impaired glucose metabolism

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM SALT; NEUROLEPTIC AGENT;

AGE; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; GENDER; HOSPITALIZATION; HUMAN; IMPAIRED GLUCOSE METABOLISM; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SUICIDE ATTEMPT;

EID: 84976643744     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12399     Document Type: Article

References (47)

1. Fernandes BS, Gama CS, Cereser KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995–1004.
2. Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry. 2014;19:750–751.
3. Munkholm K, Vinberg M, Kessing LV. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Mol Psychiatry 2015;21:216–228.
4. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009;12:447–458.
5. Barbosa IG, Huguet RB, Mendonca VA et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett. 2010;475:95–98.
6. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology. 2014;47:199–211.
7. Bus BA, Molendijk ML, Penninx BJ et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology. 2011;36:228–239.
8. Krabbe KS, Nielsen AR, Krogh-Madsen R et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431–438.
9. Fujinami A, Ohta K, Obayashi H et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem. 2008;41:812–817.
10. Civelek S, Konukoglu D, Erdenen F, Uzun H. Serum neurotrophic factor levels in patients with type 2 diabetes mellitus: relationship to metabolic syndrome components. Clin Lab. 2013;59:369–374.
11. Boyuk B, Degirmencioglu S, Atalay H et al. Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:978143.
12. Wahlqvist ML, Lee MS, Chuang SY et al. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. BMC Med. 2012;10:150.
13. Kemp DE, Sylvia LG, Calabrese JR et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand. 2014;129:24–34.
14. Vancampfort D, Mitchell AJ, De Hert M et al. Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry 2015;76:1490–1499.
15. Association AD. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl. 1):S14–S80.
16. Baldessarini RJ, Salvatore P, Khalsa HM, Imaz-Etxeberria H, Gonzalez-Pinto A, Tohen M. Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients. J Affect Disord. 2012;136:149–154.
17. Uher R, Mantere O, Suominen K, Isometsa E. Typology of clinical course in bipolar disorder based on 18-month naturalistic follow-up. Psychol Med. 2013;43:789–799.
18. Koenders MA, de Kleijn R, Giltay EJ, Elzinga BM, Spinhoven P, Spijker AT. A network approach to bipolar Symptomatology in PATIENTS with different course types. PLoS ONE. 2015;10:e0141420.
19. Zis AP, Grof P, Webster M, Goodwin FK. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull. 1980;16:47–49.
20. Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985;317:1–34.
21. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry. 1998;172:23–28.
22. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64:680–690.
23. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003;48:458–461.
24. Calkin CV, Ruzickova M, Uher R et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015;206:52–57.
25. McIntyre RS, Soczynska JK, Konarski JZ et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry. 2007;19:257–264.
26. Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013;45:171–181.
27. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015;52:89–104.
28. Hajek T, Calkin C, Blagdon R, Slaney C, Alda M. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry. 2015;77:295–303.
29. Hajek T, Calkin C, Blagdon R, Slaney C, Uher R, Alda M. Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology. 2014;39:2910–2918.
30. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006;29:2539–2548.
31. Sahin I, Alkan A, Keskin L et al. Evaluation of in vivo cerebral metabolism on proton magnetic resonance spectroscopy in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Diabetes Complications. 2008;22:254–260.
32. Reijmer YD, Brundel M, de Bresser J, Kappelle LJ, Leemans A, Biessels GJ. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study. Diabetes Care. 2013;36:137–144.
33. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31:858–873.
34. Strakowski SM, Adler CM, Almeida J et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012;14:313–325.
35. Cowansage KK, LeDoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol. 2010;3:12–29.
36. Zagrebelsky M, Korte M. Form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacology. 2014; 76 Pt C:628–638.
37. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–817.
38. Burkhalter J, Fiumelli H, Allaman I, Chatton JY, Martin JL. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci. 2003;23:8212–8220.
39. Markham A, Cameron I, Bains R et al. Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. Eur J Neurosci. 2012;35:366–374.
40. Suwa M, Kishimoto H, Nofuji Y et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism. 2006;55:852–857.
41. Golden E, Emiliano A, Maudsley S et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS ONE. 2010;5:e10099.
42. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother. 2011;11:1017–1028.
43. Tasci I, Kabul HK, Aydogdu A. Brain derived neurotrophic factor (BDNF) in cardiometabolic physiology and diseases. Anadolu Kardiyol Derg. 2012;12:684–688.
44. Faria MC, Goncalves GS, Rocha NP et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J Psychiatr Res. 2014;53:166–172.
45. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology. 2001;158:100–106.
46. Chen PS, Peng GS, Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry. 2006;11:1116–1125.
47. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci. 2001;14:135–144.